Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Change in Receivables for 14 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 50.28% year-over-year to $1.6 million, compared with a TTM value of $775000.0 through Dec 2025, up 270.33%, and an annual FY2025 reading of $236000.0, up 111.99% over the prior year.
  • Change in Receivables was $1.6 million for Q4 2025 at Enanta Pharmaceuticals, up from -$1.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $4.1 million in Q4 2021 and bottomed at -$11.6 million in Q1 2021.
  • Average Change in Receivables over 5 years is -$1.2 million, with a median of $591500.0 recorded in 2022.
  • The sharpest move saw Change in Receivables crashed 1325.03% in 2023, then soared 343.08% in 2024.
  • Year by year, Change in Receivables stood at $4.1 million in 2021, then crashed by 44.33% to $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then soared by 343.08% to $1.1 million in 2024, then soared by 50.28% to $1.6 million in 2025.
  • Business Quant data shows Change in Receivables for ENTA at $1.6 million in Q4 2025, -$1.5 million in Q3 2025, and $1.5 million in Q2 2025.